Oncology (TOI) | Financial Analysis & Statements
The Oncology Institute Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
142.0M
Gross Profit
22.8M
16.04%
Operating Income
-6.9M
-4.87%
Net Income
-7.5M
-5.29%
EPS (Diluted)
$-0.06
Balance Sheet Metrics
Total Assets
164.7M
Total Liabilities
180.4M
Shareholders Equity
-15.7M
Cash Flow Metrics
Operating Cash Flow
6.9M
Free Cash Flow
2.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Oncology Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 502.7M | 393.4M | 324.2M | 252.5M | 203.0M |
| Cost of Goods Sold | 426.3M | 339.4M | 264.7M | 200.4M | 162.2M |
| Gross Profit | 76.4M | 54.0M | 59.6M | 52.1M | 40.8M |
| Gross Margin % | 15.2% | 13.7% | 18.4% | 20.6% | 20.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 105.6M | 107.8M | 113.9M | 119.7M | 83.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 105.6M | 107.8M | 113.9M | 119.7M | 83.4M |
| Operating Income | -36.1M | -60.1M | -60.2M | -72.0M | -45.9M |
| Operating Margin % | -7.2% | -15.3% | -18.6% | -28.5% | -22.6% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 11.3M | 7.5M | 6.8M | 4.1M | 320.0K |
| Other Non-Operating Income | -13.4M | 3.0M | -16.2M | 76.0M | 34.6M |
| Pre-tax Income | -60.7M | -64.7M | -83.1M | -91.0K | -11.6M |
| Income Tax | -131.0K | 0 | -36.0K | -243.0K | -671.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -60.6M | -64.7M | -83.1M | 152.0K | -10.9M |
| Net Margin % | -12.1% | -16.4% | -25.6% | 0.1% | -5.4% |
| Key Metrics | |||||
| EBITDA | -30.1M | -54.2M | -55.0M | -67.1M | -41.5M |
| EPS (Basic) | - | $-0.71 | $-0.92 | $0.02 | $-0.16 |
| EPS (Diluted) | - | $-0.71 | $-0.92 | $-0.20 | $-0.16 |
| Basic Shares Outstanding | - | 75043678 | 73748660 | 72793497 | 66230606 |
| Diluted Shares Outstanding | - | 75043678 | 73748660 | 72793497 | 66230606 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Oncology Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 33.6M | 49.7M | 33.5M | 14.0M | 114.3M |
| Short-term Investments | - | 0 | 49.4M | 59.8M | 0 |
| Accounts Receivable | 59.0M | 48.3M | 42.4M | 39.8M | 20.0M |
| Inventory | 16.9M | 10.0M | 13.7M | 9.3M | 6.4M |
| Other Current Assets | 3.0M | 4.0M | - | - | - |
| Total Current Assets | 112.7M | 112.4M | 143.5M | 130.4M | 154.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 24.1M | 27.4M | 31.5M | 26.0M | 967.0K |
| Goodwill | 25.5M | 29.3M | 32.4M | 60.8M | 71.5M |
| Intangible Assets | 11.0M | 14.8M | 17.9M | 18.0M | 18.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 606.0K | 589.0K | 561.0K | 477.0K | 320.0K |
| Total Non-Current Assets | 51.9M | 60.3M | 65.7M | 131.2M | 49.4M |
| Total Assets | 164.7M | 172.7M | 209.2M | 261.7M | 203.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 43.2M | 24.3M | 14.4M | 9.4M | 15.6M |
| Short-term Debt | 7.2M | 6.8M | 6.4M | 5.5M | 183.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.3M | - | 3.6M | 3.2M | 2.6M |
| Total Current Liabilities | 71.0M | 52.2M | 34.8M | 29.7M | 29.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 96.5M | 116.4M | 113.3M | 102.7M | 0 |
| Deferred Tax Liabilities | 0 | 32.0K | 32.0K | 108.0K | 371.0K |
| Other Non-Current Liabilities | 28.0K | 125.0K | 365.0K | 868.0K | 6.9M |
| Total Non-Current Liabilities | 109.4M | 116.9M | 117.4M | 108.8M | 69.5M |
| Total Liabilities | 180.4M | 169.1M | 152.2M | 138.5M | 99.3M |
| Equity | |||||
| Common Stock | 10.0K | 8.0K | 8.0K | 7.0K | 7.0K |
| Retained Earnings | -271.4M | -210.8M | -146.2M | -63.1M | -63.2M |
| Treasury Stock | 1.0M | 1.0M | 1.0M | 0 | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -15.7M | 3.6M | 57.0M | 123.2M | 104.2M |
| Key Metrics | |||||
| Total Debt | 103.7M | 123.2M | 119.7M | 108.2M | 183.0K |
| Working Capital | 41.8M | 60.2M | 108.7M | 100.7M | 124.3M |
Balance Sheet Composition
Oncology Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -60.6M | -64.7M | -83.1M | 152.0K | -10.9M |
| Depreciation & Amortization | 6.9M | 6.3M | 5.9M | 4.4M | 3.3M |
| Stock-Based Compensation | 4.6M | 11.2M | 17.8M | 27.7M | 24.5M |
| Working Capital Changes | -260.0K | 7.4M | -3.9M | -27.3M | -1.3M |
| Operating Cash Flow | -41.0M | -33.5M | -57.9M | -52.1M | -10.4M |
| Investing Activities | |||||
| Capital Expenditures | -3.2M | -3.8M | -4.6M | -5.5M | -2.8M |
| Acquisitions | - | 0 | -4.5M | -8.6M | -9.1M |
| Investment Purchases | - | 0 | -9.6M | -117.5M | 0 |
| Investment Sales | 0 | 50.0M | 81.3M | 0 | - |
| Investing Cash Flow | -3.1M | 46.2M | 62.6M | -131.6M | -12.0M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | -1.0M | -9.0M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | 0 | 110.0M | 0 |
| Debt Repayment | -20.0M | -39.0K | -101.0K | -58.0K | -7.3M |
| Financing Cash Flow | 8.1M | -3.6M | -7.0M | 91.3M | 154.0M |
| Free Cash Flow | -27.8M | -30.3M | -40.9M | -67.3M | -35.7M |
| Net Change in Cash | -36.0M | 9.1M | -2.3M | -92.3M | 131.6M |
Cash Flow Trend
Oncology Key Financial Ratios
Valuation Ratios
Forward P/E
-21.50
Price to Book
-20.91
Price to Sales
0.68
PEG Ratio
-21.50
Profitability Ratios
Profit Margin
-12.06%
Operating Margin
-4.87%
Return on Equity
320.01%
Return on Assets
-13.37%
Financial Health
Current Ratio
1.59
Debt to Equity
-6.60
Beta
0.20
Per Share Data
EPS (TTM)
$-0.54
Book Value per Share
$-0.16
Revenue per Share
$5.44
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TOI | 323.2M | - | -20.91 | 320.01% | -12.06% | -6.60 |
| HCA Healthcare | 106.0B | 16.86 | -38.44 | -244.82% | 8.97% | -17.57 |
| Tenet Healthcare | 16.5B | 12.17 | 3.88 | 27.02% | 6.60% | 160.79 |
| Surgery Partners | 1.9B | 2,956.00 | 1.09 | 2.76% | -2.35% | 114.51 |
| Pediatrix Medical | 1.9B | 11.88 | 2.16 | 20.28% | 8.64% | 73.29 |
| Astrana Health | 1.9B | 73.30 | 2.12 | 4.49% | 0.71% | 193.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






